Navigation Links
Sinovac to Present at the 2008 UBS Global Life Sciences Conference

BEIJING, Sept. 17 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that Mr. Weidong Yin, Chairman, president & CEO, will present at 2008 UBS Global Life Sciences Conference, at Grant Hyatt Beijing Hotel in New York City. The Presentation is scheduled for Tuesday, September 23, 2008 at 12:00 PM.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, . To be added to our distribution list, please email:

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910



Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: /

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
2. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
3. Sinovac Adjourns Annual General Meeting
4. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
5. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
6. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
7. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
8. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
9. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
10. Sinovac Biotech Holds Annual General Meeting
11. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... 25, 2015 , ... Jessica Richman and Zachary Apte, founders ... initial angel funding process. Now, they are paying it forward to other microbiome ... investments in the microbiome space. In this, they join other successful entrepreneurs-turned-angels ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology:
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):